Literature DB >> 22124165

Radiotracers for different angiogenesis receptors in a melanoma model.

Érica A Oliveira1, Bluma L Faintuch, Eutímio Gustavo F Núñez, Ana Maria Moro, Prasant K Nanda, Charles J Smith.   

Abstract

Early and reliable diagnosis of melanoma, a skin tumor with a poor prognosis, is extremely important. Phage display peptide libraries are a convenient screening resource for identifying bioactive peptides that interact with cancer targets. The aim of this study was to evaluate two technetium-99m tracers for angiogenesis detection in a melanoma model, using cyclic pegylated pentapeptide with RGD and NGR motifs conjugated with the bifunctional chelator mercaptoacetyltriglycine (MAG(3)). The conjugated peptides (10 μl of a μg/μl solution) were labeled with technetium-99m using a sodium tartrate buffer. Radiochemical evaluation was carried out by instant thin-layer chromatography and confirmed by high-performance liquid chromatography. The partition coefficient was determined and internalization assays were performed in two melanoma cell lines (B16F10 and SKMEL28). Biodistribution evaluation of the tracers was carried out in healthy animals at different time points and also in tumor-bearing mice, 120 min post injection. Blocking studies were also conducted by coinjection of cold peptides. The conjugates displayed a rather similar pharmacokinetic profile. They were radiolabeled with high radiochemical purity (>97%) and both were hydrophilic with preferential renal excretion. Yet, tumor uptake was higher for human than for murine melanoma cells, especially for [(99m)Tc]-MAG(3)-PEG(8)-c(RGDyk) (7.85±2.34%injected dose/g 120 min post injection). The performance of [(99m)Tc]-MAG(3)-PEG(8)-c(RGDyk) was better than the NGR tracer with regard to human melanoma uptake. In this sense, it should be considered for future radiotracer studies of tumor diagnosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22124165     DOI: 10.1097/CMR.0b013e32834e6a7e

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

1.  Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo.

Authors:  Irene Tsiapa; George Loudos; Eirini A Fragogeorgi; Penelope Bouziotis; Dimitrios Psimadas; Stavros Xanthopoulos; Maria Paravatou-Petsotas; Lazaros Palamaris; Alexandra D Varvarigou; Dimitris Karnabatidis; George C Kagadis
Journal:  Cancer Biother Radiopharm       Date:  2014-12       Impact factor: 3.099

Review 2.  Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.

Authors:  Circe D van der Heide; Simone U Dalm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-05       Impact factor: 9.236

3.  Functional investigation of bone implant viability using radiotracers in a new model of osteonecrosis.

Authors:  Luis Schiper; Bluma Linkowski Faintuch; Roberto José da Silva Badaró; Erica Aparecida de Oliveira; Victor E Arana Chavez; Elisangela Chinen; Joel Faintuch
Journal:  Clinics (Sao Paulo)       Date:  2016-10-01       Impact factor: 2.365

Review 4.  Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.

Authors:  Liqin Zhu; Zhikai Ding; Xingliang Li; Hongyuan Wei; Yue Chen
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.